Vyleesi and High Blood Pressure
A bottom-funnel, evidence-led guide for women already comparing treatment, safety, access, cost, or practical use.
Last reviewed: August 26, 2026 · Editorial review completed · Medical reviewer not yet assigned
Who wrote and reviewed this page?
Low desire is a symptom. The cause is the part worth figuring out.
If menopause symptoms, sleep changes, vaginal discomfort or hormonal shifts are part of the picture, use the calculator to organize what is happening before your next appointment.
Check My Menopause Pattern → Free educational assessment. Not a diagnosis or prescription.What is actually being compared?
The useful comparison is cardiovascular screening before as-needed therapy. Women searching this topic are usually past the awareness stage. They already know a drug name, a formulation, or an HSDD treatment category and are deciding whether the option fits their situation. That means the page needs to answer the decision question directly rather than wander into a generic essay about libido.
One of the biggest traps in this category is treating all low sexual desire as the same condition. The current Addyi and Vyleesi labels define acquired, generalized HSDD around low sexual desire that causes marked distress or interpersonal difficulty and is not due to another medical or psychiatric condition, a relationship problem, or the effects of medication or another drug substance. Those exclusions matter because they can completely change the treatment path.
Direct comparison
| Item | Current guidance |
|---|---|
| Situation | Label position |
| Uncontrolled hypertension | Contraindicated |
| Known cardiovascular disease | Contraindicated |
| High cardiovascular risk | Not recommended |
| Well-controlled blood pressure | Still requires clinical risk assessment |
| Dose spacing | No more than one dose within 24 hours |
Why eligibility matters more than marketing
Addyi and Vyleesi have different current labeled populations and different routines. Addyi’s December 2025 U.S. labeling expanded the indication to women younger than 65 with acquired, generalized HSDD. Vyleesi’s current label remains for premenopausal women with acquired, generalized HSDD. Old articles that still describe Addyi as premenopausal-only are therefore stale.
Neither medication is labeled as a general aphrodisiac or sexual-performance enhancer. The decision starts with whether the symptoms meet the labeled HSDD framework and whether another issue is driving the complaint. A patient with painful intercourse from vaginal dryness, for example, may need the pain and genitourinary problem addressed rather than having the entire problem reduced to “low libido.”
You can compare drugs all day. Your symptom pattern still decides what deserves attention.
Use the menopause calculator to see whether hot flashes, sleep disruption, vaginal symptoms, mood changes or other menopause-related issues may be sitting underneath the problem you are trying to solve.
See What My Symptoms Suggest → Use the result as a discussion aid with a licensed clinician.Safety and practical trade-offs
Addyi and Vyleesi have materially different safety profiles. Addyi carries important hypotension and syncope precautions, including specific alcohol-timing instructions, a contraindication with moderate or strong CYP3A4 inhibitors, and a contraindication in hepatic impairment. It can also cause central nervous system depression such as sleepiness or sedation.
Vyleesi can cause a transient rise in blood pressure and decrease in heart rate after each dose. It is contraindicated in uncontrolled hypertension or known cardiovascular disease and is not recommended in patients at high cardiovascular risk. Its label also warns about nausea and focal hyperpigmentation. These are not footnotes to hide beneath a conversion button. They are reasons why the “best” drug depends on the person.
Cost, insurance, and access
Coverage and out-of-pocket cost should be verified for the exact prescription. Brand-name drugs can sit on different formulary tiers, require prior authorization, use a preferred pharmacy, or be excluded entirely. Cash prices and manufacturer assistance can also change. For that reason, this site does not invent a national “average price” and pretend it applies to every pharmacy and plan.
For a clean comparison, ask the insurer or pharmacy for the exact product, strength, quantity or package, prior-authorization status, preferred dispensing channel, deductible impact, and monthly out-of-pocket amount. For Vyleesi, also consider expected number of doses per month. For Addyi, compare a recurring monthly daily-medication cost rather than a cost per event.
Questions to take to the clinician
- Do my symptoms actually meet the diagnostic and labeled framework for acquired, generalized HSDD?
- Could another medication, depression, relationship stress, vaginal pain, sleep disruption, or menopause symptom be driving the problem?
- Does menopause status or age change which FDA-approved options fit?
- Which contraindications or interactions in my history matter most?
- Would a daily treatment or an as-needed treatment better fit my routine?
- What would count as meaningful improvement by the eight-week review point?
- What should make me stop the medication and contact the clinic?
Related sexual-health medication guides
Turn this medication research into a useful next step.
You now know more about vyleesi and high blood pressure. Map your broader menopause symptoms next, then bring both pieces of information to your clinician instead of trying to diagnose yourself from scattered search results.
Take the Menopause Calculator → Educational only. Treatment decisions require professional evaluation.Frequently asked questions
Is low sexual desire always HSDD?
No. The labeled HSDD indication excludes low desire that is better explained by another medical or psychiatric condition, relationship problem, or medication/substance effect.
Can a menopause symptom cause low desire without HSDD?
Yes. Sleep disruption, vaginal dryness or pain, hot flashes, mood symptoms, and other menopause-related problems can affect desire. Those causes may call for a different treatment plan.
Are Addyi and Vyleesi performance-enhancing drugs?
No. Their labels state that they are not indicated to enhance sexual performance.
Can I buy these safely from an unverified supplement website?
Prescription drugs should come through licensed healthcare and pharmacy channels. FDA has warned about sexual-enhancement products containing hidden drug ingredients.
How long should treatment continue if there is no benefit?
Both current labels instruct discontinuation after 8 weeks if symptoms do not improve.
Does menopause status matter?
Yes. Current Addyi labeling covers women younger than 65, including eligible postmenopausal women. Vyleesi remains labeled for premenopausal women.
Can I choose based only on price?
No. Route, contraindications, interactions, adverse effects, medical history, and treatment pattern can matter more than price.
Should my current medication list be reviewed?
Yes. Medication effects can contribute to low desire, and Addyi in particular has important drug-interaction rules.
What if sex is painful?
Pain or vaginal dryness should be evaluated rather than assumed to be HSDD. Genitourinary syndrome of menopause and other conditions may need direct treatment.
What should I ask my clinician?
Ask whether your symptoms meet HSDD criteria, whether another condition or medication could explain them, which treatment routes fit your health history, what risks matter most, and how success will be measured.
Primary sources
- DailyMed: Addyi (flibanserin) current U.S. prescribing information
- DailyMed: Vyleesi (bremelanotide) current U.S. prescribing information
- FDA: warning about hidden flibanserin in sexual-enhancement products
Label information checked August 26, 2026. Drug labeling, availability, insurance rules, and manufacturer programs can change.